Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BB Biotech AGXSWX:BION -1.12%33 Intrinsic Value: Projected FCF is CHF85.38 as of Aug. 17, 2026, which is 100% below its 10-year median of 0.82. GuruFocus rates XSWX:BION with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 259 Biotechnology companies, BB Biotech AG ranks better than 89.58% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-17), BB Biotech AG's Intrinsic Value: Projected FCF is CHF85.38. The stock price of BB Biotech AG is CHF53.10. Therefore, BB Biotech AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.6.
The historical rank and industry rank for BB Biotech AG's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:BION'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.45 Med: 0.82 Max: 3.05
Current: 0.62
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of BB Biotech AG was 3.05. The lowest was 0.45. And the median was 0.82.
XSWX:BION's Price-to-Projected-FCF is ranked better than 89.58% of 259
companies
in the Biotechnology industry
Industry Median: 2.21
vs XSWX:BION: 0.62
BB Biotech AG (XSWX:BION) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
BB Biotech AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
53.10
/
85.37835011656
=
0.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG Intrinsic Value: Projected FCF Related Terms
BB Biotech AG Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG Intrinsic Value: Projected FCF Chart
XSWX:BION vs VRTX, REGN, RVMD: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, BB Biotech AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Price-to-Projected-FCF falls into.
BB Biotech AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF85.38 mean?
BB Biotech AG (XSWX:BION) has a Intrinsic Value: Projected FCF of CHF85.38 as of Aug. 17, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BB Biotech AG and its competitors. This is 10312% above median its historical median of 0.82. Over the past decade, BB Biotech AG's Intrinsic Value: Projected FCF has ranged from 0.45 to 3.05. According to the industry distribution chart, BB Biotech AG ranks #27 out of 259 companies in the Biotechnology industry, placing it in the top 10.4%.
Is BB Biotech AG's Intrinsic Value: Projected FCF too high?
BB Biotech AG's current Intrinsic Value: Projected FCF of CHF85.38 is 10312% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 3.05. Based on the distribution chart, BB Biotech AG ranks #27 out of 259 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BB Biotech AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #27 out of 259 companies for Intrinsic Value: Projected FCF. This places BB Biotech AG in the top 10% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 2.21. Historically, BB Biotech AG's own Intrinsic Value: Projected FCF has ranged from 0.45 to 3.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.21, based on 259 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BB Biotech AG and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current Intrinsic Value: Projected FCF is CHF85.38, which is 10312% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Intrinsic Value: Projected FCF of CHF85.38. The current Intrinsic Value: Projected FCF is CHF85.38, which is 10312% above median its 10-year median of 0.82. BB Biotech AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Intrinsic Value: Projected FCF is CHF85.38 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
33GF Score
Get the complete analysis for XSWX:BION
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 
